STOCK TITAN

Barrick Mining Corporation Stock Price, News & Analysis

B NYSE

Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.

Barnes Group Inc. (NYSE: B) maintains its position as a global leader in precision industrial technologies and aerospace solutions. This news hub provides investors and industry professionals with essential updates on corporate developments, financial performance, and strategic initiatives.

Access timely updates spanning earnings announcements, product innovations, and operational milestones. Our curated collection features official press releases alongside market analysis relevant to Barnes Grp's industrial and aerospace segments.

Key coverage areas include manufacturing advancements in transportation systems, aerospace component developments, and strategic partnerships across global markets. The repository serves as a reliable resource for understanding the company's impact on sectors ranging from healthcare infrastructure to defense technologies.

Bookmark this page for streamlined access to Barnes Grp's latest financial disclosures and operational updates. Regularly refreshed content ensures stakeholders maintain current awareness of this engineering leader's market position and technological contributions.

Rhea-AI Summary

Barnes Group Inc. (NYSE: B) reported Q2 2024 financial results, showing sales of $382 million, up 13% year-over-year with organic growth of 5%. The company recorded an operating loss of $2.1 million due to a $53.7 million non-cash impairment charge in the Automation business unit. Adjusted operating income was $47.6 million, up 9%, with adjusted operating margin at 12.4%, down 40 bps. Adjusted EBITDA was $76.5 million, up 14%, with a margin of 20.0%, up 20 bps. Barnes reported a net loss of $46.8 million, or -$0.91 per share, compared to net income of $17.4 million, or $0.34 per share in the prior year. Adjusted EPS was $0.37, down 36% from $0.58 last year. The company updated its 2024 guidance, projecting organic sales growth of 4% to 6% and adjusted EPS of $1.55 to $1.75.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
-
Rhea-AI Summary

BioArctic AB announced that its partner Eisai will present new data on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) 2024. Key presentations include:

1. Three-year efficacy and safety data from Phase 2 and 3 studies
2. Mechanism of action targeting toxic soluble aggregated amyloid-beta protofibrils
3. Importance of maintenance treatment based on neurodegenerative biomarkers
4. Long-term imaging and fluid biomarkers
5. Evidence supporting continued lecanemab dosing

BioArctic will also present a poster on Nordic healthcare system's readiness for new Alzheimer's treatments. Lecanemab, developed through BioArctic and Eisai's collaboration, entitles BioArctic to milestone payments, 9% royalties on global sales, and Nordic region commercialization rights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
-
Rhea-AI Summary

Barnes Aerospace's Taoyuan, Taiwan site has received MTU Maintenance Hannover GmbH's Number One Supplier Award for the second consecutive six-month evaluation period. The award, presented during a May 2024 supplier recognition ceremony, is based on MTU's Supplier Evaluation Tool (SET) which assesses key performance indicators including turnaround time, quality, and reliability.

MTU Maintenance Hannover GmbH's Manager of Customer Accounts, Markus Breuer, praised Barnes Aerospace's customer service team for their dedication and capability in developing and industrializing repairs. Johnson Hsu, General Manager of Barnes Aerospace–Taoyuan, noted that MTU has grown with them by more than 300% in the last five years. The award underscores Barnes Aerospace's commitment to operational excellence and outstanding customer support.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
News
Rhea-AI Summary

Barnes Group Inc. (NYSE: B) has announced a quarterly cash dividend of $0.16 per share, payable on September 10, 2024, to shareholders of record as of August 22, 2024. This declaration continues Barnes' long-standing tradition of dividend payments, which has been maintained by the company and its predecessors since 1934. The consistent dividend payout demonstrates Barnes' commitment to providing regular returns to its shareholders and reflects the company's financial stability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
dividends
-
Rhea-AI Summary

BioArctic's partner Eisai announced that Leqembi® (lecanemab) has been approved for Alzheimer's disease (AD) treatment in Israel. The approval is based on the Phase 3 Clarity AD study, which showed that Leqembi met its primary and secondary endpoints with statistically significant results. Israel is the sixth region to approve Leqembi, following the US, Japan, China, South Korea, and Hong Kong. Leqembi works by selectively binding to amyloid-beta aggregates, reducing plaques in the brain. BioArctic, which developed the antibody, will receive milestone payments, a 9% royalty on global sales, and has the right to commercialize Leqembi in the Nordic region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
Rhea-AI Summary

BioArctic's partner Eisai announced that the Department of Health in Hong Kong has approved Leqembi (lecanemab) for treating Alzheimer's disease. The approval is based on the successful Phase 3 Clarity AD study, which demonstrated statistically significant results in slowing cognitive decline. Hong Kong is the fifth country to approve Leqembi, following the US, Japan, China, and South Korea. Leqembi targets amyloid-beta aggregates to reduce disease progression. BioArctic will commercialize Leqembi in the Nordic region, pending European approval, and will receive a 9% royalty on global sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
News
Rhea-AI Summary

BioArctic AB's partner Eisai has announced the launch of Leqembi® (lecanemab) in China on June 28, 2024. Approved in January 2024 for treating mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD), Leqembi is now available in the United States, Japan, and China. Eisai estimates there are 17 million early AD patients in China. The drug will be available in the private market with a 200 mg vial priced at CNY 2,508. A specialized healthcare insurance plan partially covering the drug cost has been introduced. Leqembi, which reduces amyloid-beta (Aβ) plaques in the brain, is the first treatment shown to slow disease progression. BioArctic will receive milestone payments and a 9% royalty on global sales, with plans to commercialize the drug in the Nordic region pending European approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary

Barnes Group (NYSE: B) will release its second quarter 2024 financial results on Friday, July 26, 2024, before the market opens. The company will host a conference call at 8:30 a.m. (ET) to discuss the results and the company’s outlook. The call can be accessed via a live audio webcast on the Investor Relations section of the Barnes website or by dialing (888) 510-2379 in the U.S. or (646) 960-0691 internationally, using Conference ID 1137078. Supplemental materials will be posted on the company's website before the call. A recording of the call will be available for playback from 12:00 p.m. (ET) on July 26, 2024, until 11:59 p.m. (ET) on August 2, 2024, by dialing (609) 800-9909 and using Playback ID 1137078.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
-
Rhea-AI Summary

During the MRO Americas show in Chicago, Barnes Aerospace and RTX’s Pratt & Whitney Canada announced a long-term extension to their repair services agreement. This partnership, which began in the 1970s, focuses on the maintenance, repair, and overhaul of complex aero engine components. Barnes Aerospace aims to leverage its repair capabilities and expertise to meet the growing demand for support of existing and new engine programs, ensuring industry-leading turn-around times.

Pratt & Whitney Canada, with over 68,000 engines in service, highlighted the importance of this agreement in maintaining a reliable network of service partners to keep their engines operational. Certified by various regulatory authorities, Barnes Aerospace provides services to major commercial airlines and original equipment manufacturers worldwide. The agreement aims to advance new repair development solutions and supports engines currently in development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
Rhea-AI Summary

The FDA has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly intravenous (IV) maintenance dosing of Leqembi® (lecanemab-irmb) for early Alzheimer's Disease (AD). A Prescription Drug User Fee Act (PDUFA) action date is set for January 25, 2025. Leqembi is designed to treat patients with mild cognitive impairment or mild dementia. The sBLA is based on data from the Phase 2 Study 201, its open-label extension (OLE), and the Clarity AD study. If approved, the monthly dosing regimen would be less burdensome, aiding long-term treatments. Eisai has also initiated a rolling submission to the FDA for a Leqembi subcutaneous autoinjector for weekly dosing. Leqembi is currently approved in several countries, and BioArctic is entitled to payments and royalties from its sales, with rights to commercialize in the Nordic region pending European approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags

FAQ

What is the current stock price of Barrick Mining Corporation (B)?

The current stock price of Barrick Mining Corporation (B) is $20.82 as of June 30, 2025.

What is the market cap of Barrick Mining Corporation (B)?

The market cap of Barrick Mining Corporation (B) is approximately 36.4B.
Barrick Mining Corporation

NYSE:B

B Rankings

B Stock Data

36.42B
1.70B
9.25%
90.69%
1.98%
Specialty Industrial Machinery
Miscellaneous Fabricated Metal Products
Link
United States
BRISTOL